genomic and epigenomic analysis in inflammatory bowel disease for investigation of pathogenes and resistance to anti-TNF therapy the mechanisms of

genomic and epigenomic analysis in inflammatory bowel disease for investigation of pathogenes and resistance to anti-TNF therapy the mechanisms of - genomic and epigenomic analysis in inflammatory bowel disease for investigation of pathogenes and the mechanisms of resistance to anti-TNF therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005435

Enrollment

Registered

2011-04-14

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients with Crohn's disease who will be received anti-TNFa antibody therapy

Exclusion criteria

Exclusion criteria: the patients that we cannot obtain the agreement (by IC form) about this study.

Design outcomes

Primary

Measure	Time frame
epigenomic alteration response to anti-TNFa antibody	—

Countries

Japan

Contacts

Public ContactTADAKAZU HISAMATSU

School of Medicine, Keio University Div. of Gastroenterology and hepatology, Dep. of Internal Medicine,

hisamachi@a7.keio.jp03-3353-1211

Outcome results